Key facts
- This page summarizes Alex D'Amico's Form 3 filing for Cytosorbents Corp (CTSO).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 15 Aug 2023, 17:57.
Alex D'Amico - 07 Aug 2023 Form 3 Insider Report for Cytosorbents Corp (CTSO)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CTSO
- Reported as of
- 07 Aug 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 15 Aug 2023, 17:57:07 UTC
- Prior SEC filing
- 03 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alexander D'Amico, by attorney-in-fact Kathleen P. Bloch
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alex D'Amico filed Form 3 for Cytosorbents Corp (CTSO) on 15 Aug 2023.
Change
- Previous filing in this sequence was filed on 03 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTSO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 210,000
- Date
- 07 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTSO
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 07 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 70,000
- Exercise price
- $3.48
- Footnotes
- F2
CTSO
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 07 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 215,000
- Exercise price
- $3.48
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Consists of (a) 45,000 restricted stock units ("RSUs"), which will vest 1/2 on the first anniversary of the date of grant and 1/2 on the second anniversary of the date of grant, subject to the executive officer's continued service with the Company as of the applicable vesting date, (b) 15,000 RSUs which will vest either upon a Change of Control or will cliff vest on the second anniversary of the date of grant, subject to the executive officer's continued service with the Company as of the applicable vesting date and (c) 150,000 RSUs which will vest only upon a Change in Control, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"), subject to the executive officer's continued service with the Company as of the applicable vesting date.
Footnote F2
These stock options ("Annual ISOs") were granted pursuant to the Plan and will vest in accordance with the following schedule, in each case, subject to the executive officer's continued service with the Company as of the applicable vesting date: 25,000 Annual ISOs upon the six-month anniversary of the date of grant and 15,000 Annual ISOs upon each of the first, second and third anniversaries of the date of grant.
Footnote F3
These stock options ("Performance ISOs") were granted pursuant to the Plan and will vest only upon the achievement of certain milestones pursuant to the terms of the Company's existing 2022-2025 performance pool in place for the Company's management team, subject to the executive officer's continued service with the Company as of the applicable vesting date.
SEC remarks
Exhibit 24 - Power of Attorney